Clinical Trials
60 trialsNCT07432295 2026-05-14
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07407465 2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04534218 2024-12-20
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT02743221 2024-08-20
TASCO1
Servier
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT05438706 2022-06-30
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT02595320 2021-12-20
X7-7
University of Kansas Medical Center
Phase 2 Unknown
NCT03858972 2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT01387373 2020-10-05
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
Herlev Hospital
Phase 2 Completed
NCT01471353 2020-07-23
SorCape
University of Florida
Phase 2 Completed
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT00444678 2020-04-03
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT01396707 2020-01-07
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Asan Medical Center
Phase 2 Completed
NCT02007148 2019-02-27
MICADO
International Group of Endovascular Oncology
Phase 2 Unknown
NCT00483834 2019-02-15
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT03588533 2018-07-17
HERZUMA-GC
Dong-A University Hospital
Phase 2 Unknown
NCT02474186 2017-08-03
Phase II Study for Solid Metastatic Tumors
NYU Langone Health
Phase 2 Completed
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT01130805 2016-04-15
A Study of Pazopanib With CAPEOX in AGC Patients
Samsung Medical Center
Phase 2 Completed
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01703910 2015-10-09
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 2 Completed
NCT01067989 2015-07-08
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT01472770 2014-12-04
GemCaP
Vejle Hospital
Phase 2 Completed
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT01322152 2013-06-11
Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer
Fudan University
Phase 2 Completed
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00534417 2013-02-01
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed
NCT00967031 2013-01-18
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
Phase 2 Completed
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00122291 2012-01-19
A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer
AHS Cancer Control Alberta
Phase 2 Unknown
NCT00629148 2011-07-07
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
Fudan University
Phase 2 Completed
NCT00270491 2011-02-25
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
ARCAGY/ GINECO GROUP
Phase 2 Completed